Status | Study |
Recruiting |
Study Name: Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies Condition: Proteus Syndrome PIK3CA-Related Overgrowth Spectrum (PROS) Date: 2017-03-17 Interventions: Drug: ARQ 092 Subjects will receive ARQ 092 orally at the dose level and administration schedule specifi |
Recruiting |
Study Name: Familial Investigations of Childhood Cancer Predisposition Condition: Acute Leukemia Adenomatous Polyposis Adrenocortical Carcin Date: 2017-02-08 |
Recruiting |
Study Name: RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN) Condition: PTEN Gene Mutation PTEN Hamartoma Tumor Syndrome Date: 2016-12-02 Interventions: Drug: RAD001 |
Recruiting |
Study Name: Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Condition: Basal Cell Carcinoma Date: 2015-12-14 Interventions: Drug: Vismodegib Vismodegib 150 mgs po qd for 3 months |
Enrolling by invitation |
Study Name: Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome Condition: Proteus Syndrome Date: 2015-10-31 Interventions: Drug: ARQ 092 |
Recruiting |
Study Name: Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations Condition: PTEN ASD Autism Macrocep Date: 2015-05-11 |
Recruiting |
Study Name: French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperplastic Polyposis Condition: Quality of Life Date: 2013-11-12 Interventions: Other: Procedure surgery behavioral and genetic diagnosis |
Active, not recruiting |
Study Name: A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas Condition: Basal Cell Carcinoma Date: 2013-03-19 Interventions: Drug: Vismodegib Vismodegib 15 |
Completed |
Study Name: Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas Condition: Basal Cell Nevus Syndrome Gorlin's Syndrome Date: 2012-03-14 Interventions: Drug: Vismodegib 150 mg per da |
Completed |
Study Name: Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants Condition: Coronary Artery Disease Proteus Syndrome Coffin - Sins Syn Date: 2011-06-08 |